Across TCGA pan-cancer cohorts, RPL39P25 RNA differs between tumor and matched normal tissue in 2 of 18 cancer types tested, making tumor–normal expression one of RPL39P25’s most consistent transcriptional readouts.

The strongest signal is observed in breast invasive carcinoma (BRCA), where RPL39P25 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types RPL39P25 is over-expressed in tumor.

BRCA and KIRC are the cancer types where RPL39P25 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in RPL39P25 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
BRCA	Female	All	+0.051	.023	4	view →
KIRC	All	All	+0.058	.009	3	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 2 strongest of 2 lineages.

Exploration

Same gene, other analysis: RPL39P25 RNA expression & survival · all RPL39P25 data types